<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02073929</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT nr 2013-003862-15</org_study_id>
    <nct_id>NCT02073929</nct_id>
  </id_info>
  <brief_title>LIPT - Liraglutide in Polycystic Ovary Syndrome</brief_title>
  <acronym>LIPT</acronym>
  <official_title>A Randomised, Double-blind, Placebo-controlled Study of the Effect of Liraglutide in Polycystic Ovary Syndrome on Risk Markers of Vascular Thrombosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jens Faber</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polycystic ovary syndrome (PCOS) affects 5-10% of women in fertile age. PCOS is associated
      with metabolic syndrom, diabetes and and increased risk og cardiovascular disease.

      The study investigates the effect af intervention with GLP-1-analog on risk markers of
      cardiovascular disease in women with PCOS.

      70 women will be included in af RCT.

      Hypothesis: GLP-1-analog treatment in women with PCOS (without diabetes) will result in a
      beneficial reduction in risk markers of vascular thrombosis and early cardiovascular disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Endogenous Thrombin Potential (ETP)</measure>
    <time_frame>at time 0 and 26 weeks</time_frame>
    <description>Area under curve in a Thrombin Generation Test (TGT). Measurements every min for 10 min</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Plasma Level of Plasminogen Activator Inhibitor -1 PAI-1</measure>
    <time_frame>at time 0 and 26 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Plasma Level of Adrenomedullin</measure>
    <time_frame>at time 0 and 26 weeks</time_frame>
    <description>measured in nmol/l</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Plasma Level of Atrial Natriuretic Peptide (ANP)</measure>
    <time_frame>at time 0 and 26 weeks</time_frame>
    <description>measured in pmol/l</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Plasma Level of Copeptin</measure>
    <time_frame>at time 0 and 26 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change in Plasma Level of High Sensitivity C-reactive Protein (CRP)</measure>
    <time_frame>at time 0 and 26 weeks</time_frame>
    <description>percent change from baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Bleeding Pattern (Bleeding Ratio)</measure>
    <time_frame>at time 0 and 26 weeks</time_frame>
    <description>Ration between number of bleedings during 3 months before trial and last 3 months of trial</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Percent Liver Fat Content</measure>
    <time_frame>at time 0 and 26 weeks</time_frame>
    <description>percent liver fat content</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Body Composition (VAT)</measure>
    <time_frame>at time 0 and 26 weeks</time_frame>
    <description>cubic cm</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Ovarian Volume Between Baseline and Follow up (26 Weeks)</measure>
    <time_frame>at time 0 and 26 weeks</time_frame>
    <description>measured as ml</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Serum Levels of Anti-Müllerian Hormone</measure>
    <time_frame>at time 0 and 26 weeks</time_frame>
    <description>measured as pmol/l</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liraglutide s.c. 1,8mg daily for 26 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo s.c. daily for 26 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide for 26 weeks</intervention_name>
    <description>GLP-1-analogue Liraglutide s.c. 1,8mg daily for 26 weeks</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo s.c. daily for 26 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PCOS

          -  &gt;18 years

          -  premenopausal

          -  BMI &gt;25 og 25 and thereunder + insulin resistent

        Exclusion Criteria (including):

          -  actualt or intended pregnancy

          -  inadeqvat contraception

          -  hormonal contraception within 6 weeks

          -  metfoomin, GLP-1-analog or DPP IV inhibitor within 3 months

          -  medications affectiv hemostatic mechanisme

          -  diabetes or other severe comorbidity

          -  familar MEN

          -  ...
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Faber, DSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Medicine, Herlev Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Medicine and Dept. of Gyn-Obs, Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital, Dept of Gynecology</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Medicine and Dept. of Obstetrics and Gynaecology, Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>DK-2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>February 25, 2014</study_first_submitted>
  <study_first_submitted_qc>February 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2014</study_first_posted>
  <results_first_submitted>June 20, 2017</results_first_submitted>
  <results_first_submitted_qc>February 27, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 28, 2019</results_first_posted>
  <last_update_submitted>February 27, 2019</last_update_submitted>
  <last_update_submitted_qc>February 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Jens Faber</investigator_full_name>
    <investigator_title>Professor, DSc, Senior Hospital Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Liraglutide</title>
          <description>Liraglutide s.c. 1,8mg daily for 26 weeks
Liraglutide: GLP-1-analogue Liraglutide</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo s.c. 1,8mg daily for 26 weeks
placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Liraglutide</title>
          <description>Liraglutide</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.4" lower_limit="24.6" upper_limit="35.6"/>
                    <measurement group_id="B2" value="26.2" lower_limit="24.8" upper_limit="31.5"/>
                    <measurement group_id="B3" value="29.9" lower_limit="24.7" upper_limit="34.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>women</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>caucasians</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>other ethnicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.3" spread="5.1"/>
                    <measurement group_id="B2" value="33.3" spread="4.6"/>
                    <measurement group_id="B3" value="33.3" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist Circumference</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102.6" spread="10.8"/>
                    <measurement group_id="B2" value="102.6" spread="11.1"/>
                    <measurement group_id="B3" value="102.6" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total testosterone</title>
          <units>nmol/l</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.23" lower_limit="0.91" upper_limit="1.63"/>
                    <measurement group_id="B2" value="1.35" lower_limit="0.95" upper_limit="1.93"/>
                    <measurement group_id="B3" value="1.30" lower_limit="0.92" upper_limit="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Endogenous Thrombin Potential</title>
          <units>micromol/l x min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1796" spread="332"/>
                    <measurement group_id="B2" value="1830" spread="285"/>
                    <measurement group_id="B3" value="1801" spread="324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Endogenous Thrombin Potential (ETP)</title>
        <description>Area under curve in a Thrombin Generation Test (TGT). Measurements every min for 10 min</description>
        <time_frame>at time 0 and 26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide s.c. 1,8mg daily for 26 weeks
Liraglutide: GLP-1-analogue Liraglutide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo s.c. 1,8mg daily for 26 weeks
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Endogenous Thrombin Potential (ETP)</title>
          <description>Area under curve in a Thrombin Generation Test (TGT). Measurements every min for 10 min</description>
          <units>nMolar x minutes</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-56.7" lower_limit="-132.3" upper_limit="17.2"/>
                    <measurement group_id="O2" value="-8.2" lower_limit="-98.7" upper_limit="82.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Plasma Level of Plasminogen Activator Inhibitor -1 PAI-1</title>
        <time_frame>at time 0 and 26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide s.c. 1,8mg daily for 26 weeks
Liraglutide: GLP-1-analogue Liraglutide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo s.c. 1,8mg daily for 26 weeks
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Plasma Level of Plasminogen Activator Inhibitor -1 PAI-1</title>
          <units>percent change in plasma PAI-1</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12" lower_limit="-23" upper_limit="0"/>
                    <measurement group_id="O2" value="4" lower_limit="-14" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Plasma Level of Adrenomedullin</title>
        <description>measured in nmol/l</description>
        <time_frame>at time 0 and 26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide s.c. 1,8mg daily for 26 weeks
Liraglutide: GLP-1-analogue Liraglutide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo s.c. 1,8mg daily for 26 weeks
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Level of Adrenomedullin</title>
          <description>measured in nmol/l</description>
          <units>nmol/l</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" lower_limit="-0.04" upper_limit="0.002"/>
                    <measurement group_id="O2" value="0.003" lower_limit="-0.02" upper_limit="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Plasma Level of Atrial Natriuretic Peptide (ANP)</title>
        <description>measured in pmol/l</description>
        <time_frame>at time 0 and 26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide s.c. 1,8mg daily for 26 weeks
Liraglutide: GLP-1-analogue Liraglutide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo s.c. 1,8mg daily for 26 weeks
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Level of Atrial Natriuretic Peptide (ANP)</title>
          <description>measured in pmol/l</description>
          <units>pmol/l</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.5" lower_limit="-17.0" upper_limit="-6.1"/>
                    <measurement group_id="O2" value="1.4" lower_limit="-7.5" upper_limit="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Plasma Level of Copeptin</title>
        <time_frame>at time 0 and 26 weeks</time_frame>
        <population>measured as pmol/l</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide s.c. 1,8mg daily for 26 weeks
Liraglutide: GLP-1-analogue Liraglutide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo s.c. 1,8mg daily for 26 weeks
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Level of Copeptin</title>
          <population>measured as pmol/l</population>
          <units>pmol/l</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" lower_limit="-0.39" upper_limit="1.34"/>
                    <measurement group_id="O2" value="0.28" lower_limit="-0.51" upper_limit="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change in Plasma Level of High Sensitivity C-reactive Protein (CRP)</title>
        <description>percent change from baseline</description>
        <time_frame>at time 0 and 26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide s.c. 1,8mg daily for 26 weeks
Liraglutide: GLP-1-analogue Liraglutide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo s.c. 1,8mg daily for 26 weeks
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Plasma Level of High Sensitivity C-reactive Protein (CRP)</title>
          <description>percent change from baseline</description>
          <units>percent change in CRP levels</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15" lower_limit="-30" upper_limit="3"/>
                    <measurement group_id="O2" value="-25" lower_limit="-57" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Bleeding Pattern (Bleeding Ratio)</title>
        <description>Ration between number of bleedings during 3 months before trial and last 3 months of trial</description>
        <time_frame>at time 0 and 26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide s.c. 1,8mg daily for 26 weeks
Liraglutide: GLP-1-analogue Liraglutide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo s.c. 1,8mg daily for 26 weeks
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bleeding Pattern (Bleeding Ratio)</title>
          <description>Ration between number of bleedings during 3 months before trial and last 3 months of trial</description>
          <units>n of bleedings/n of expected bleedings</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" lower_limit="0.20" upper_limit="0.36"/>
                    <measurement group_id="O2" value="0.14" lower_limit="0.02" upper_limit="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Percent Liver Fat Content</title>
        <description>percent liver fat content</description>
        <time_frame>at time 0 and 26 weeks</time_frame>
        <population>only participants with measurable i.e. &gt;5% liver fat at baseline was included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide s.c. 1,8mg daily for 26 weeks
Liraglutide: GLP-1-analogue Liraglutide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo s.c. 1,8mg daily for 26 weeks
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percent Liver Fat Content</title>
          <description>percent liver fat content</description>
          <population>only participants with measurable i.e. &gt;5% liver fat at baseline was included in this analysis</population>
          <units>percentage of liver fat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="0.4"/>
                    <measurement group_id="O2" value="-0.2" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Body Composition (VAT)</title>
        <description>cubic cm</description>
        <time_frame>at time 0 and 26 weeks</time_frame>
        <population>not measured on all subjects (missing. 4 in Liraglutide and one in placebo Group)</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide s.c. 1,8mg daily for 26 weeks
Liraglutide: GLP-1-analogue Liraglutide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo s.c. 1,8mg daily for 26 weeks
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Composition (VAT)</title>
          <description>cubic cm</description>
          <population>not measured on all subjects (missing. 4 in Liraglutide and one in placebo Group)</population>
          <units>cubic cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17" spread="4"/>
                    <measurement group_id="O2" value="5" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Ovarian Volume Between Baseline and Follow up (26 Weeks)</title>
        <description>measured as ml</description>
        <time_frame>at time 0 and 26 weeks</time_frame>
        <population>not measured in all participants, one is missing in each group</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide s.c. 1,8mg daily for 26 weeks
Liraglutide: GLP-1-analogue Liraglutide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo s.c. 1,8mg daily for 26 weeks
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ovarian Volume Between Baseline and Follow up (26 Weeks)</title>
          <description>measured as ml</description>
          <population>not measured in all participants, one is missing in each group</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" lower_limit="-3" upper_limit="-1"/>
                    <measurement group_id="O2" value="0" lower_limit="-2" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Serum Levels of Anti-Müllerian Hormone</title>
        <description>measured as pmol/l</description>
        <time_frame>at time 0 and 26 weeks</time_frame>
        <population>missing one participant in placebo group</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide s.c. 1,8mg daily for 26 weeks
Liraglutide: GLP-1-analogue Liraglutide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo s.c. 1,8mg daily for 26 weeks
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Levels of Anti-Müllerian Hormone</title>
          <description>measured as pmol/l</description>
          <population>missing one participant in placebo group</population>
          <units>pmol/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.7" lower_limit="-17.4" upper_limit="0.6"/>
                    <measurement group_id="O2" value="3.5" lower_limit="-13.9" upper_limit="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Active</title>
          <description>Liraglutide s.c. 1,8mg daily for 26 weeks
Liraglutide: GLP-1-analogue Liraglutide</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo s.c. 1,8mg daily for 26 weeks
placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>gallbladder stone attack</sub_title>
                <description>gallbladder stone attack / gallstone related pain</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <description>nausea in up-titrating phase</description>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Jens Faber</name_or_title>
      <organization>Center of Endocrinology and Metabolism, Dept. of Internal Medicine, Herlev Gentofte Hospital, Denmark</organization>
      <phone>+4538689016</phone>
      <email>jens.faber@regionh.dk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

